Now showing items 1-1 of 1
Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
(İstanbul İl Sağlık Müdürlüğü, 2019)
OBJECTIVE: Stage III disease accounts for approximately one-fourth of all non-metastatic non-small cell lung cancer (NSCLC). The patients who are not candidates for curative resection are offered concomitant chemoradiotherapy. ...